Skip to main content
. 2021 Dec 10;23(2):131. doi: 10.3892/etm.2021.11054

Figure 4.

Figure 4

miR-603 negatively regulates FGF9 expression and FGF9 is a target of miR-603. (A) Bioinformatics analysis of miR-603 binding sites in FGF9. (B) Relative luciferase activity of FHCs co-transfected with miR-NC, miR-603 mimics, and FGF9-WT and FGF9-MUT. (C) Relative FGF9 expression in FHCs in the different treatment groups. (D) The MTT bioassay was performed to assess cell viability in the different treatment groups. (E) Expression levels of different cytokines in LPS-treated FHCs. All experiments were performed in triplicate. **P<0.01 vs. miR-NC. miR, microRNA; FGF9, fibroblast growth factor 9; FHCS, fetal human cells; NC, negative control; WT, wild-type; MUT, mutant; LPS, lipopolysaccharide; OD, optical density; TNF, tumor necrosis factor; IL, interleukin.